{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:31:47Z","timestamp":1788831107913,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["JPMH21HA2008"],"award-info":[{"award-number":["JPMH21HA2008"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0108612"],"award-info":[{"award-number":["JP21fk0108612"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22fk0108637"],"award-info":[{"award-number":["JP22fk0108637"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015060","name":"Nagasaki University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.vaccine.2023.10.021","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T16:29:36Z","timestamp":1697214576000},"page":"6969-6979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1\/BA.2 and BA.5 in Japan"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5215-1500","authenticated-orcid":false,"given":"Takeshi","family":"Arashiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Kuramochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumi","family":"Chubachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Arioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genei","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Nagura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7256-4994","authenticated-orcid":false,"given":"Hideki","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Numata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7853-5721","authenticated-orcid":false,"given":"Hideaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Ooki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nidaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Asami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torahiko","family":"Jinta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Taniyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kankuro","family":"Ueshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Fuwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2243-5999","authenticated-orcid":false,"given":"Ashley","family":"Stucky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9238-3202","authenticated-orcid":false,"given":"Chris","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8587-1849","authenticated-orcid":false,"given":"Martin","family":"Hibberd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koya","family":"Ariyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.10.021_b0005","unstructured":"Coronavirus disease (COVID-19) pandemic. World Health Organization. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019."},{"issue":"27","key":"10.1016\/j.vaccine.2023.10.021_b0010","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2023.10.021_b0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.vaccine.2023.10.021_b0020","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.vaccine.2023.10.021_b0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"10.1016\/j.vaccine.2023.10.021_b0030","doi-asserted-by":"crossref","first-page":"753","DOI":"10.15585\/mmwr.mm7020e2","article-title":"Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel - 33 U.S. sites, January-March 2021","volume":"70","author":"Pilishvili","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.10.021_b0035","article-title":"Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study","volume":"374","author":"Chung","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.vaccine.2023.10.021_b0040","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by Covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2023.10.021_b0045","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2023.10.021_b0050","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N Engl J Med"},{"issue":"10309","key":"10.1016\/j.vaccine.2023.10.021_b0055","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2023.10.021_b0060","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2023.10.021_b0065","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.vaccine.2023.10.021_b0070","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2023.10.021_b0075","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants","volume":"327","author":"Accorsi","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2023.10.021_b0080","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants","volume":"28","author":"Tseng","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.10.021_b0085","article-title":"COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection during Delta-dominant and Omicron-dominant periods in Japan: a multi-center prospective case-control study (FASCINATE study)","author":"Arashiro","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2023.10.021_b0090","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/s41591-022-01911-2","article-title":"Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa","volume":"28","author":"Tegally","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.10.021_b0095","unstructured":"Coronavirus disease (COVID-19) weekly epidemiological update. World Health Organization. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports."},{"key":"10.1016\/j.vaccine.2023.10.021_b0100","unstructured":"Visualizing the data: information on COVID-19 infections. Ministry of Health, Labour and Welfare, Japan. https:\/\/covid19.mhlw.go.jp\/en\/."},{"key":"10.1016\/j.vaccine.2023.10.021_b0105","unstructured":"Lineage detection in SARS-CoV-2 genomic surveillance [in Japanese]. Ministry of Health, Labour and Welfare, Japan. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/newpage_00061.html."},{"issue":"7923","key":"10.1016\/j.vaccine.2023.10.021_b0110","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.021_b0115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMc2206576","article-title":"Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5","volume":"387","author":"Hachmann","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2023.10.021_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004107","article-title":"Global SARS-CoV-2 seroprevalence: a systematic review and meta-analysis of standardized population-based studies from Jan 2020-May 2022","volume":"19","author":"Bergeri","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2023.10.021_b0125","unstructured":"Policy responses to the coronavirus pandemic. Our World in Data. https:\/\/ourworldindata.org\/policy-responses-covid."},{"issue":"2","key":"10.1016\/j.vaccine.2023.10.021_b0130","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13094","article-title":"National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan","volume":"17","author":"Arashiro","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2023.10.021_b0135","unstructured":"Preliminary results of the seroprevalence study using donor blood [in Japanese]. Ministry of Health, Labour and Welfare, Japan. https:\/\/www.mhlw.go.jp\/content\/10900000\/001018624.pdf."},{"key":"10.1016\/j.vaccine.2023.10.021_b0140","unstructured":"Mask use. Ministry of Health, Labour and Welfare, Japan. https:\/\/www.mhlw.go.jp\/stf\/covid-19\/mask.html."},{"key":"10.1016\/j.vaccine.2023.10.021_b0145","unstructured":"About COVID-19 vaccines [in Japanese]. Ministry of Health, Labour and Welfare, Japan. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/vaccine_00184.html."},{"key":"10.1016\/j.vaccine.2023.10.021_b0150","unstructured":"Variant-specific PCR results [in Japanese]. Ministry of Health, Labour and Welfare, Japan. https:\/\/www.mhlw.go.jp\/content\/10900000\/000888045.pdf."},{"key":"10.1016\/j.vaccine.2023.10.021_b0155","unstructured":"Estimated BA.5 prevalence based on data from the SARS-CoV-2 genomic surveillance [in Japanese]. Ministry of Health, Labour and Welfare, Japan. https:\/\/www.mhlw.go.jp\/content\/10900000\/000892298.pdf."},{"key":"10.1016\/j.vaccine.2023.10.021_b0160","unstructured":"COVID-19 vaccine surveillance report: 4 August 2022 (week 31). UK Health Security Agency. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1096327\/Vaccine_surveillance_report_week_31_2022.pdf."},{"key":"10.1016\/j.vaccine.2023.10.021_b0165","unstructured":"About variants of concern: 21st report [in Japanese]. National Institute of Infectious Diseases, Japan. https:\/\/www.niid.go.jp\/niid\/ja\/2019-ncov\/2551-cepr\/11572-sars-cov-2-21.html."},{"issue":"5","key":"10.1016\/j.vaccine.2023.10.021_b0170","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/irv.12992","article-title":"Behavioral factors associated with SARS-CoV-2 infection in Japan","volume":"16","author":"Arashiro","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.021_b0175","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1093\/cid\/ciac234","article-title":"Effects of confounding bias in coronavirus disease 2019 (COVID-19) and influenza vaccine effectiveness test-negative designs due to correlated influenza and COVID-19 vaccination behaviors","volume":"75","author":"Doll","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"42","key":"10.1016\/j.vaccine.2023.10.021_b0180","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.15585\/mmwr.mm7142a3","volume":"71","author":"Surie","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.10.021_b0185","article-title":"Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. Lancet","author":"Tartof","year":"2022","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.vaccine.2023.10.021_b0190","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S1473-3099(22)00692-2","article-title":"BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5","volume":"22","author":"Tartof","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10328","key":"10.1016\/j.vaccine.2023.10.021_b0195","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2023.10.021_b0200","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1056\/NEJMc2213948","article-title":"Immunogenicity of BA.5 bivalent mRNA vaccine boosters","volume":"388","author":"Collier","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2023.10.021_b0205","first-page":"240","article-title":"Effectiveness of BA.1- and BA.4\/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan. Open Forum","volume":"10","author":"Arashiro","year":"2023","journal-title":"Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2023.10.021_b0210","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.vaccine.2023.10.021_b0215","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2023.10.021_b0220","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/irv.13023","article-title":"Ascertainment of vaccination status by self-report versus source documentation: impact on measuring COVID-19 vaccine effectiveness","volume":"16","author":"Stephenson","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2023.10.021_b0225","doi-asserted-by":"crossref","DOI":"10.2196\/44465","article-title":"Accuracy of self-reported COVID-19 vaccination status compared with a public health vaccination registry in Qu\u00e9bec: observational diagnostic study","volume":"9","author":"Archambault","year":"2023","journal-title":"JMIR Public Health Surveill"},{"key":"10.1016\/j.vaccine.2023.10.021_b0230","doi-asserted-by":"crossref","unstructured":"Lewis NM, Murray N, Adams K, et al. Absolute and relative vaccine effectiveness of primary and booster series of COVID-19 vaccines (mRNA and adenovirus vector) against COVID-19 hospitalizations in the United States, December 2021-April 2022. Open Forum Infect Dis 2022;10(1):ofac698. https:\/\/doi.org\/10.1093\/ofid\/ofac698.","DOI":"10.1093\/ofid\/ofad252"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:30:36Z","timestamp":1759404636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23011945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":46,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0264410X23011945"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1\/BA.2 and BA.5 in Japan","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}